---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000105"
form_type: "8-K"
ticker: null
cik: "0001722964"
company_name: "Y-mAbs Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:19:42.385838+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Y-mAbs realigns into two units, cuts ~13% staff; FY24 rev ~$88M; GD2-SADA data Q2 2025

## Summary
- Preliminary FY2024 total net revenue ~$88M (guidance $87-95M); cash ~$67M; cash investment ~$11M (below $15-20M guidance).
- Workforce reduction of up to ~13% as part of realignment into DANYELZA and Radiopharmaceutical business units.
- SVP/Chief Commercial Officer Susan Smith departs April 9, 2025; Doug Gentilcore named SVP Danyelza Unit Head, Natalie Tucker promoted to SVP Radiopharma Head.
- GD2-SADA Phase 1 Part A (21 patients) well-tolerated, no DLTs; Part A data expected in Q2 2025.
- CD38-SADA first patient dosing expected Q1 2025; potential DANYELZA ex-US approval in 2025.

## SEC filing metadata
- accession: 0001558370-25-000105
- form_type: 8-K
- cik: 0001722964
- company_name: Y-mAbs Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/0001558370-25-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/ymab-20250106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000105
- JSON: https://secwatch.observer/filing/0001558370-25-000105.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000105.txt

## Key facts
- Executive change
  Susan Smith departed as Senior Vice President and Chief Commercial Officer at Y-mAbs Therapeutics, Inc..
  - Action: will be departing
  - Role: Senior Vice President and Chief Commercial Officer
  source text: Susan Smith, the Company’s Senior Vice President and Chief Commercial Officer, will be departing from the Company on April 9, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/0001558370-25-000105-index.htm
- Restructurings & Charges
  Y-mAbs Therapeutics, Inc. announced a restructuring with charges of up to approximately $2.6 million affecting not explicitly segmented but refers to two business units: DANYELZA and Radiopharmaceuticals (up to approximately 13%).
  - Type: restructuring
  - Charge: up to approximately $2.6 million
  - Affected area: not explicitly segmented but refers to two business units: DANYELZA and Radiopharmaceuticals
  - Headcount: up to approximately 13%
  source text: healthcare coverage assistance. ​ As a result of the reduction in workforce and realignment plan, the Company expects to incur restructuring expenses of up to approximately $2.6 million, consisting predominantly of cash-related notice and severance payments of up to approximately $2.1 million and acceleration of stock-based compensation of up to approximately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/0001558370-25-000105-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.